NASDAQ: CYCC |
| Healthcare / Biotechnology / USA |
1.39 | +0.0100 | +0.72% | Vol 769.58K | 1Y Perf -78.93% |
Jun 27th, 2022 16:00 DELAYED |
BID | 1.35 | ASK | 1.43 | ||
Open | 1.40 | Previous Close | 1.38 | ||
Pre-Market | - | After-Market | 1.42 | ||
- - | 0.03 2.16% |
Target Price | 20.00 | Analyst Rating | Strong Buy 1.00 | |
Potential % | 1.34K | Finscreener Ranking | — - | |
Insiders Trans % 3/6/12 mo. | -/-/100 | Value Ranking | ★★★★ 55.30 | |
Insiders Value % 3/6/12 mo. | -/-/100 | Growth Ranking | — - | |
Insiders Shares Cnt. % 3/6/12 mo. | -/-/100 | Income Ranking | — - | |
Price Range Ratio 52W % | 6.08 | Earnings Rating | Strong Buy | |
Market Cap | 13.89M | Earnings Date | 10th Aug 2022 | |
Alpha | -0.06 | Standard Deviation | 0.23 | |
Beta | 1.41 |
Today's Price Range 1.331.42 | 52W Range 1.056.64 | 5 Year PE Ratio Range -0.8000-1.10 |
Summary:
Neutral
Technical Indicators: | Neutral |
Moving Averages: | Sell |
Performance | |||
---|---|---|---|
1 Week | -0.71% | ||
1 Month | 14.88% | ||
3 Months | -55.87% | ||
6 Months | -63.71% | ||
1 Year | -78.93% | ||
3 Years | -87.14% | ||
5 Years | -98.30% | ||
10 Years | -99.81% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -36.98 | |||
ROE last 12 Months | -50.06 | |||
ROA (5Y Avg) | -17.06 | |||
ROA last 12 Months | -44.53 | |||
ROC (5Y Avg) | -49.94 | |||
ROC last 12 Months | -47.85 | |||
Return on invested Capital Q | -11.77 | |||
Return on invested Capital Y | -13.59 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-0.60 | ||||
0.36 | ||||
88.29 | ||||
- | ||||
-0.60 | ||||
-2.25 | ||||
0.36 | ||||
3.34 | ||||
-17 530 100.00 | ||||
Forward PE | -0.36 | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
5.50 | ||||
5.90 | ||||
0.00 | ||||
0.00 | ||||
- | ||||
Leverage Ratio | 1.10 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
-6 235.30 | ||||
-6 220.70 | ||||
- | ||||
- |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
0.00 | ||||
0.00 | ||||
- | ||||
- |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q01 2022 | -0.67 | -0.42 | 37.31 |
Q04 2021 | -0.71 | -0.54 | 23.94 |
Q03 2021 | -0.70 | -0.54 | 22.86 |
Q02 2021 | -0.47 | -0.56 | -19.15 |
Q01 2021 | -0.45 | -0.50 | -11.11 |
Q04 2020 | -0.52 | -1.34 | -157.69 |
Q03 2020 | -0.49 | -0.47 | 4.08 |
Q02 2020 | -0.47 | -0.58 | -23.40 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
6/2022 QR | -0.67 | 11.84 | Positive |
9/2022 QR | -0.54 | 35.71 | Positive |
12/2022 FY | -2.15 | 46.38 | Positive |
12/2023 FY | -3.19 | 29.58 | Positive |
Next Report Date | 10th Aug 2022 |
Estimated EPS Next Report | -0.67 |
Estimates Count | 3 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 769.58K |
Shares Outstanding | 9.99K |
Shares Float | 9.67M |
Trades Count | 2.22K |
Dollar Volume | 1.06M |
Avg. Volume | 488.74K |
Avg. Weekly Volume | 809.78K |
Avg. Monthly Volume | 381.68K |
Avg. Quarterly Volume | 274.76K |
Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC) stock closed at 1.39 per share at the end of the most recent trading day (a 0.72% change compared to the prior day closing price) with a volume of 769.58K shares and market capitalization of 13.89M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 12 people. Cyclacel Pharmaceuticals Inc. CEO is Spiro Rombotis.
The one-year performance of Cyclacel Pharmaceuticals Inc. stock is -78.93%, while year-to-date (YTD) performance is -64.27%. CYCC stock has a five-year performance of -98.3%. Its 52-week range is between 1.05 and 6.64, which gives CYCC stock a 52-week price range ratio of 6.08%
Cyclacel Pharmaceuticals Inc. currently has a PE ratio of -0.60, a price-to-book (PB) ratio of 0.36, a price-to-sale (PS) ratio of 88.29, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -44.53%, a ROC of -47.85% and a ROE of -50.06%. The company’s profit margin is -%, its EBITDA margin is -6 220.70%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Cyclacel Pharmaceuticals Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.67 for the next earnings report. Cyclacel Pharmaceuticals Inc.’s next earnings report date is 10th Aug 2022.
The consensus rating of Wall Street analysts for Cyclacel Pharmaceuticals Inc. is Strong Buy (1), with a target price of $20, which is +1 338.85% compared to the current price. The earnings rating for Cyclacel Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Cyclacel Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Cyclacel Pharmaceuticals Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 16.50, ATR14 : 0.12, CCI20 : 152.43, Chaikin Money Flow : -0.02, MACD : -0.05, Money Flow Index : 56.17, ROC : 13.11, RSI : 51.68, STOCH (14,3) : 82.50, STOCH RSI : 0.93, UO : 57.81, Williams %R : -17.50), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Cyclacel Pharmaceuticals Inc. in the last 12-months were: Samuel L. Barker (Buy at a value of $5 000), Spiro Rombotis (Buy at a value of $18 000)
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include CYC065 CDK inhibitor, Sapacitabine and seliciclib, CYC682, CYC140 PLK inhibitor, and CYC202. It earns the majority of its revenue from the United Kingdom.
CEO: Spiro Rombotis
Telephone: +1 908 517-7330
Address: 200 Connell Drive, Berkeley Heights 07922, NJ, US
Number of employees: 12
Tue, 12 Apr 2022 16:15 GMT Cyclacel Pharmaceuticals (CYCC) Gets a Buy Rating from Brookline Capital Markets
- TipRanks. All rights reserved.Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE EDGX Top real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2022. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.